ロード中...
MON-608 Incidence And Onset Of Thyroid Dysfunction In Patients Treated With Pd-1 Inhibitors At A Medical Center
Background: The programmed cell death-1 (PD-1) pathway is a novel therapeutic target in immune checkpoint therapy for cancer. Pembrolizumab and Nivolumab are anti-PD-1 monoclonal antibodies. Thyroid dysfunction is a known adverse effect of these drugs, but there is limited data on incidence.(1,2) Ou...
保存先:
| 出版年: | J Endocr Soc |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Endocrine Society
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6550566/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-608 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|